Advertisement

Auraptene in the Peels of Citrus Kawachiensis (Kawachibankan) Contributes to the Preservation of Cognitive Function: A Randomized, Placebo-Controlled, Double-Blind Study in Healthy Volunteers

  • Michiya Igase
  • Y. Okada
  • M. Ochi
  • K. Igase
  • H. Ochi
  • S. Okuyama
  • Y. Furukawa
  • Y. Ohyagi
Original Research
  • 4 Downloads

Abstract

Objectives

Dementia, which is characterized by a progressive decline in cognitive function, is a major concern in aging societies. Although a number of treatments have been approved, an effective therapy to prevent the disorder is lacking. A supplement that improves cognitive function would benefit patients. The aim of this study was to assess whether auraptene, a citrus coumarin, has a protective effect on cognitive decline.

Design

A randomized, placebo-controlled, double-blind study

Setting

Outpatient medical check-up program for cognitive disorders

Participants

84 adult volunteers (they are cognitively normal) met inclusion and exclusion criteria to participate.

Intervention

42 participants received auraptene enriched (containing 6.0 mg/day of auraptene) test juice, and another participants received placebo juice.

Measurements

1) Mild Cognitive Impairment (MCI) Screen using the 10-word immediate recall test. 2) The Mini-Mental State Examination (MMSE). Cognitive assessment ware carried out baseline and at 24 weeks.

Results

Auraptene enriched test juice did not improve cognitive function after 24 weeks compared with baseline data. However, there was a significant difference in the percentage change in cognitive function between the test and placebo orange juice groups (6.3 ± 18.9 vs. −2.4 ± 14.8, P < 0.05). Multiple regression analysis demonstrated a significant independent relationship between the percentage change in the 10-word immediate recall test score and test juice consumption including baseline 10-word immediate recall test score in all subjects.

Conclusion

This is the first study to assess the effectiveness of auraptene in the prevention of cognitive decline. Our results suggest that auraptene is a safe supplement for the prevention of cognitive decline.

Key words

Auraptene Kawachibankan randomized trial multiple regression analysis 10-word immediate recall test cognitive decline prevention 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Tariq S, Barber PA. Dementia risk and prevention by targeting modifiable vascular risk factors. J Neurochem, 2017. doi:10.1111/jnc.14132.Google Scholar
  2. 2.
    Livingston G, Sommerlad A, Orgeta V, Costafreda SG, Huntley J, Ames D, Ballard C, Banerjee S, Burns A, Cohen-Mansfield J, Cooper C, Fox N, Gitlin LN, Howard R, Kales HC, Larson EB, Ritchie K, Rockwood K, Sampson EL, Samus Q, Schneider LS, Selbæk G, Teri L, Mukadam N. Dementia prevention, intervention, and care. Lancet, 2017. doi:10.1016/S0140-6736(17)31363-6.Google Scholar
  3. 3.
    Beaubrun G, Gray GE. A review of herbal medicines for psychiatric disorders. Psychiatr Serv. 2000;51:1130–4.CrossRefPubMedGoogle Scholar
  4. 4.
    Genovese S, Epifano F. Auraptene:a natural biologically active compoundwith multiple targets, Curr. Drug Targets 2011;12:381–386.CrossRefGoogle Scholar
  5. 5.
    Murakami A, Nakamura Y, Tanaka T, Kawabata K, Takahashi D, Koshimizu K, Ohigashi H. Suppression by citrus auraptene of phorbol ester-andendotoxin-induced inflammatory responses:role of attenuation of leukocyteactivation, Carcinogenesis 2000;21:1843–50.CrossRefPubMedGoogle Scholar
  6. 6.
    Furukawa Y, Okuyama S, Amakura Y, Watanabe S, Fukata T, Nakajima M, Yoshimura M, Yoshida T. Isolation and characterization of activators of ERK/MAPK from Citrus plants. International Journal of Molecular Sciences 2012;13:1832–45.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Amakura Y, Yoshimura M, Ouchi K, Okuyama S, Furukawa Y, Yoshida T. Characterization of constituents in peel of Citrus kawachiensis (Kawachibankan). Bioscience, Biotechnology, and Biochemistry 2013;77:1977–80.CrossRefPubMedGoogle Scholar
  8. 8.
    Okuyama S, Yamamoto K, Mori H, Toyoda N, Yoshimura M, Amakura Y, Yoshida T, Sugawara K, Sudo M, Nakajima M, Furukawa Y. Auraptene in the peels of Citruskawachiensis (Kawachi Bankan) ameliorates lipopolysaccharide-inducedinflammation in the mouse brain, Evid Based Complement Alternat Med, 2014. doi:10.1155/2014/408503.Google Scholar
  9. 9.
    Ghanbarabadi M, Iranshahi M, Amoueian S, Mehri S, Motamedshariaty VS, Mohajeri SA. Neuroprotective and memory enhancing effects of auraptene in a rat model of vascular dementia:Experimental study and histopathological evaluation. Neuroscience Letters 2016;623, 13–21.CrossRefPubMedGoogle Scholar
  10. 10.
    Okada Y, Kohara K, Ochi M, Nagai T, Tabara Y, Igase M, Miki T. Mechanical stresses, arterial stiffness, and brain small vessel diseases:Shimanami Health Promoting Program Study. Stroke 2014;45:3287–3292.CrossRefPubMedGoogle Scholar
  11. 11.
    Friedewald WT, Levy RI, and Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499–502.PubMedGoogle Scholar
  12. 12.
    Gault MH, Longerich LL, and Harnett JD. Predicting glomerular function from adjusted serum creatinine. Nephron 1992;62:249–256.CrossRefPubMedGoogle Scholar
  13. 13.
    Cho A, Sugimura M, Nakano S, Yamada T. The Japanese MCI screen for early detection of Alzheimer’s disease and related disorders. Am J Alzheimers Dis Other Demen 2008;23:162–166.CrossRefPubMedGoogle Scholar
  14. 14.
    Morris JC, Heyman A, Mohs RC, Hughes JP, van Belle G, Fillenbaum G, Mellits ED, Clark C. The Consortium to establish a registry for Alzheimer’s disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer’s disease. Neurology 1989;9:1159–1165.Google Scholar
  15. 15.
    Trenkle DL, Shankle WR, Azen SP. Detecting cognitive impairment in primary care:Performance assessment of three screening instruments. J Alzheimers Dis 2007;11:323–335.CrossRefPubMedGoogle Scholar
  16. 16.
    Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–198.CrossRefPubMedGoogle Scholar
  17. 17.
    Heude B, Ducimetière P, Berr C; EVA Study. Cognitive decline and fatty acid composition of erythrocyte membranes—the EVA Study. Am J Clin Nutr 2003;77:803–8.CrossRefPubMedGoogle Scholar
  18. 18.
    Schaefer EJ, Bongard V, Beiser AS, Lamon-Fava S, Robins SJ, Au R, Tucker KL, Kyle DJ, Wilson PW, Wolf PA. Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease:the Framingham Heart Study, Arch Neurol 2006;63:1545–50.CrossRefPubMedGoogle Scholar
  19. 19.
    Tan ZS, Harris WS, Beiser AS, Au R, Himali JJ, Debette S, Pikula A, Decarli C, Wolf PA, Vasan RS, Robins SJ, Seshadri S. Red blood cell omega-3 fatty acid levels and markers of accelerated brain aging. Neurology 2012;78:658–64.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Andrieu S, Coley N, Lovestone S, Aisen PS, Vellas B. Prevention of sporadic Alzheimer’s disease:lessons learned from clinical trials and future directions. Lancet Neurol 2015;14:926–44.CrossRefPubMedGoogle Scholar
  21. 21.
    Schneider N, Yvon C. A review of multidomain interventions to support healthy cognitive ageing. J Nutr Health Aging 2013;17:252–7. doi:10.1007/s12603-012-0402-8.CrossRefPubMedGoogle Scholar
  22. 22.
    Okuyama, S.; Minami, S.; Shimada, N.; Makihata, N.; Nakajima, M.; Furukawa, Y. Anti-inflammatory and neuroprotective effects of auraptene, a citrus coumarin, following cerebral global ischemia in mice. Eur J Pharmacol 2013;699:118–123.CrossRefPubMedGoogle Scholar
  23. 23.
    Okuyama S, Morita M, Kaji M, Amakura Y, Yoshimura M, Shimamoto K, Ookido Y, Nakajima M, Furukawa Y. Auraptene Acts as an Anti-Inflammatory Agent in the Mouse Brain. Molecules 2015;20:20230–9.CrossRefPubMedGoogle Scholar

Copyright information

© Serdi and Springer Nature Switzerland AG 2017

Authors and Affiliations

  • Michiya Igase
    • 1
  • Y. Okada
    • 1
  • M. Ochi
    • 1
  • K. Igase
    • 2
  • H. Ochi
    • 1
  • S. Okuyama
    • 3
  • Y. Furukawa
    • 3
  • Y. Ohyagi
    • 1
  1. 1.Department of Geriatric Medicine and NeurologyEhime University Graduate School of MedicineToon City, EhimeJapan
  2. 2.Department of Advanced NeurosurgeryEhime University Graduate School of MedicineEhimeJapan
  3. 3.Department of Pharmaceutical Pharmacology, College of Pharmaceutical SciencesMatsuyama UniversityEhimeJapan

Personalised recommendations